XML 154 R110.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 21,640 € 21,407 € 18,341 [1]
Marketed products      
Disclosure of detailed information about intangible assets [line items]      
Concentration risk percentage 92.00%    
Other intangible assets € 12,700 11,700 11,400
Useful life, intangible assets other than goodwill (in years) 10 years    
Total: principal marketed products      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 11,683 10,752 10,341
Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 621 1,032 1,485
Useful life, intangible assets other than goodwill (in years) 10 years    
Remaining amortisation period of intangible assets material to entity 2 years    
Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 2,037 2,213 2,489
Useful life, intangible assets other than goodwill (in years) 17 years    
Remaining amortisation period of intangible assets material to entity 12 years    
Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 58 73 110
Useful life, intangible assets other than goodwill (in years) 9 years    
Remaining amortisation period of intangible assets material to entity 10 years    
Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 574 593 602
Useful life, intangible assets other than goodwill (in years) 23 years    
Remaining amortisation period of intangible assets material to entity 11 years    
Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 498 532 554
Useful life, intangible assets other than goodwill (in years) 13 years    
Remaining amortisation period of intangible assets material to entity 8 years    
Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 1,357 1,494 1,861
Useful life, intangible assets other than goodwill (in years) 14 years    
Remaining amortisation period of intangible assets material to entity 10 years    
Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 4,836 3,065 3,240
Useful life, intangible assets other than goodwill (in years) 13 years    
Remaining amortisation period of intangible assets material to entity 9 years    
Kadmon      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 1,702 € 1,750 € 0
Useful life, intangible assets other than goodwill (in years) 12 years    
Remaining amortisation period of intangible assets material to entity 11 years    
Gross value | Total: principal marketed products      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 62,827    
Gross value | Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 10,490    
Gross value | Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 3,633    
Gross value | Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 34,684    
Gross value | Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 1,360    
Gross value | Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 857    
Gross value | Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 1,966    
Gross value | Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 7,955    
Gross value | Kadmon      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 1,882    
Accumulated amortization & impairment | Total: principal marketed products      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (51,144)    
Accumulated amortization & impairment | Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (9,869)    
Accumulated amortization & impairment | Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (1,596)    
Accumulated amortization & impairment | Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (34,626)    
Accumulated amortization & impairment | Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (786)    
Accumulated amortization & impairment | Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (359)    
Accumulated amortization & impairment | Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (609)    
Accumulated amortization & impairment | Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (3,119)    
Accumulated amortization & impairment | Kadmon      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € (180)    
Bottom of range      
Disclosure of detailed information about intangible assets [line items]      
Useful life, intangible assets other than goodwill (in years) 1 year    
Top of range      
Disclosure of detailed information about intangible assets [line items]      
Useful life, intangible assets other than goodwill (in years) 25 years    
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.